Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VACl, VACh, and Alternating Regimens in Newly Diagnosed AML
NCT06532552Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jul 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat, cladribine in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Started Jul 2024; status: recruiting.
02
Drugs
tucidinostatcladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06532552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532552.